NEWPORT BEACH, Calif.–(BUSINESS WIRE)–jCyte, Inc., today announced key findings presented at AAO 2021 which demonstrated that retinitis pigmentosa (RP) patients with a baseline central visual field diameter greater than 20 degrees had a profound resp…
Author: Business Wire
Worldwide Novel Ocular Drug Delivery Devices Industry to 2030 – Featuring Aciont, AcuFocus and Allergan Among Others – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Novel Ocular Drug Delivery Devices Market: Focus on Implants, Inserts and Punctal Plugs – Distribution by Type of Drug Delivery Device, Target Indications, Type of Product and Key Geographies: Industry Trends and Global Fo…
Horizon Therapeutics Recognizes Second Annual Thyroid Eye Disease (TED) Awareness Week with New Educational and Community Building Initiative
DUBLIN–(BUSINESS WIRE)–Horizon Therapeutics Recognizes Second Annual Thyroid Eye Disease (TED) Awareness Week
Ocular Therapeutix™ to Participate at Two Upcoming Investor Conferences
BEDFORD, Mass.–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix, Inc. (Nasdaq: OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today a…
Sonoma Pharmaceuticals Reports Second Quarter FY 2022 Financial Results
WOODSTOCK, Ga.–(BUSINESS WIRE)–Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care,…
OpRegen® Clinical Data Presented at 125th Annual American Academy of Ophthalmology Meeting by Michael S. Ip, M.D.
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #LineageCellTherapeutics–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported up…
Gemini Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD) today reported its financial result…
Bayshore Pharmaceuticals Announces Commercial Launch of ANDA Approved Products
SHORT HILLS, N.J.–(BUSINESS WIRE)–Bayshore Pharmaceuticals, LLC is pleased to introduce three new FDA-approved products to their expanding portfolio. Metolazone Tablets USP, 2.5mg, 5mg and 10 mg, is the generic equivalent of Zaroxolyn Tablets. It is …
Global Ocular Drug Delivery Devices Market Expected to Grow at a CAGR of 5.3% During 2021-2027 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Ocular Drug Delivery Devices Market” report has been added to ResearchAndMarkets.com’s offering. The global ocular drug delivery devices market is expected to grow at a CAGR of around 5.3% during 2021-2027. This report on …
Horizon Therapeutics plc recibe la opinión positiva del CHMP para UPLIZNA® (inebilizumab) como monoterapia para el tratamiento de pacientes adultos con trastorno del espectro de la neuromielitis óptica (NMOSD)
DUBLIN–(BUSINESS WIRE)–Horizon Therapeutics plc (Nasdaq: HZNP) ha anunciado hoy que el Comité de Medicamentos de Uso Humano (CHMP) de la Agencia Europea de Medicamentos (EMA) ha adoptado una opinión positiva recomendando la autorización de comerciali…
ModMed® Surpasses 100 Million Patient Encounters in Eye Care
NEW ORLEANS–(BUSINESS WIRE)–At this year’s AAO Event in New Orleans, healthcare technology leader ModMed is demonstrating the latest innovations from its award winning and widely used ModMed® Ophthalmology software suite that is designed to support p…
Samenvatting: Horizon Therapeutics plc ontvangt positief CHMP-advies voor UPLIZNA® (inebilizumab) als monotherapie voor de behandeling van volwassen patiënten met neuromyelitis Optica Spectrum Disorder (NMOSD)
DUBLIN–(BUSINESS WIRE)–Horizon Therapeutics plc (Nasdaq: HZNP) heeft vandaag aangekondigd dat het Comité voor geneesmiddelen voor menselijk gebruik (CHMP) van het Europees Geneesmiddelenbureau (EMA) een positief advies heeft uitgebracht waarin het in…
New Real-World Data Show High Rate of Patient Adherence to TEPEZZA® (teprotumumab-trbw) for Thyroid Eye Disease (TED)
DUBLIN–(BUSINESS WIRE)–Horizon Therapeutics announces findings of a real-world adherence analysis of TEPEZZA (teprotumumab-trbw) for the treatment of TED at AAO 2021.
Gemini Therapeutics Announces Poster Presentation at AAO 2021
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today announced that Raj Maturi, M…
MingSight Completes a New Round of Financing to Accelerate Clinical Development in Chronic Lymphocytic Leukemia and Diabetic Macular Edema
SAN DIEGO–(BUSINESS WIRE)–MingSight Pharmaceuticals announced today the close of a pre-Series B round of $20M, led by Kaitai Capital. The proceeds will be used for the clinical development of MS-553, a new generation inhibitor of protein kinase C (PK…
Inflammasome Therapeutics’ CEO to Be Featured Speaker at Upcoming Virtual Summit on Inflammasomes
NEWTON, Mass.–(BUSINESS WIRE)– #NRTIs–Inflammasome Therapeutics’ CEO to be Featured Speaker at Virtual Summit on Inflammasomes – to discuss role of inflammasome activation in ophthalmology
Horizon Therapeutics plc erhält positive Stellungnahme des CHMP (Ausschuss für Humanarzneimittel) für UPLIZNA® (Inebilizumab) als Monotherapie zur Behandlung von erwachsenen Patienten mit einer Neuromyelitis Optica Spektrum Disorder (NMOSD)
DUBLIN–(BUSINESS WIRE)–Horizon Therapeutics plc (Nasdaq: HZNP) gab heute bekannt, dass der Ausschuss für Humanarzneimittel (CHMP) der Europäischen Arzneimittel-Agentur (EMA) eine positive Stellungnahme für die Empfehlung der Zulassung von UPLIZNA® (I…
Horizon Therapeutics plc reçoit un avis positif du CMUH pour UPLIZNA® (inébilizumab) en monothérapie pour le traitement des patients adultes atteints de troubles du spectre de la neuromyélite optique (TSNO)
DUBLIN–(BUSINESS WIRE)–Horizon Therapeutics plc (Nasdaq: HZNP) a annoncéaujourd’hui que le comité des médicaments à usage humain (CMUH) de l’Agence européenne des médicaments (AEM) a émis un avis favorable recommandant l’octroi d’une AMM pour UPLIZNA…
Horizon Therapeutics plc riceve il parere positivo del CHMP (Comitato per i medicinali per uso umano) per UPLIZNA® (inebilizumab) come monoterapia per il trattamento di pazienti adulti affetti da disturbo dello spettro della neuromielite ottica
DUBLINO–(BUSINESS WIRE)–Horizon Therapeutics plc (Nasdaq: HZNP) oggi ha annunciato che il Comitato per i medicinali per uso umano (CHMP) dell’Agenzia europea per i medicinali (EMA) ha rilasciato un parere positivo che raccomanda l’autorizzazione all’…
Horizon Therapeutics plc Receives CHMP Positive Opinion for UPLIZNA® (inebilizumab) as a Monotherapy for the Treatment of Adult Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)
DUBLIN–(BUSINESS WIRE)–Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization f…